Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 31 of 1,261
  1. US 12351839

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Precision BioSciences, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  2. US 12351649

    Antibodies to oxidation-specific epitopes

    The Regents of the University of California · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  3. US 12351633

    PD-1 and PD-L1 binding agents

    Orionis Biosciences, Inc · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  4. US 12351644

    Anti-CD73 antibodies

    Corvus Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  5. US 12351638

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    LEGEND BIOTECH USA INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  6. US 12350510

    Magnetic microwires for energy-transporting biomedical applications

    Northwestern University · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  7. US 12350322

    Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation

    United Biomedical, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  8. US 12351625

    Therapeutic antibodies against osteopontin

    United States Government as represented by the Department of Veterans Affairs · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  9. US 12351561

    Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  10. US 12351560

    Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

    The Board of Regents of the University of Texas System · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  11. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  12. US 12351611

    Molecules for organelle-specific protein delivery

    Larimar Therapeutics, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  13. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  14. US 12350274

    Nucleotide analogs

    United States Government as represented by the Department of Veterans Affairs · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  15. US 12351653

    Pharmaceutical compositions comprising novel cyclic peptides

    LISATA THERAPEUTICS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  16. US 12350270

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  17. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  18. US 12350245

    Stable oral suspensions of baclofen

    ANI Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  19. US 12350399

    Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

    The Regents of the University of California · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  20. US 12351581

    Compounds for FGFR inhibition

    Cogent Biosciences, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  21. US 12350242

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  22. US 12351587

    Bicyclic compound as RIP-1 kinase inhibitor and application thereof

    Medshine Discovery Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  23. US 12351614

    CLEC9A-based chimeric protein complexes

    Orionis Biosciences, Inc · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  24. US 12351824

    Method for producing natural killer cells from pluripotent stem cells

    Takeda Pharmaceutical Company Limited · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.